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Abstract
Introduction: Copeptin has been proposed as a prognostic marker in acute illness. This study investigated the
ability of copeptin to predict the disease outcome and cerebrovasospasm in the patients with aneurysmal
subarachnoid hemorrhage.
Methods: In this retrospective study, 303 consecutive patients were included. Upon admission, plasma copeptin
levels were measured by enzyme-linked immunosorbent assay. The end points were mortality after 1 year, in-
hospital mortality, cerebrovasospasm and poor functional outcome (Glasgow Outcome Scale score of 1-3) after 1
year.
Results: Upon admission, plasma copeptin level in patients was statistically significantly higher than that in healthy
controls. A multivariate analysis showed that plasma copeptin level was an independent predictor of poor
functional outcome and mortality after 1 year, in-hospital mortality and cerebrovasospasm. A receiver operating
characteristic curve showed that plasma copeptin level on admission predicted poor functional outcome and
mortality after 1 year, in-hospital mortality and cerebrovasospasm of patients statistically significantly. The area
under curve of the copeptin concentration was similar to those of World Federation of Neurological Surgeons
(WFNS) score and modified Fisher score for the prediction of poor functional outcome and mortality after 1 year,
and in-hospital mortality, but not for the prediction of cerebrovasospasm. In a combined logistic-regression model,
copeptin improved the area under curve of WFNS score and modified Fisher score for the prediction of poor
functional outcome after 1 year, but not for the prediction of mortality after 1 year, in-hospital mortality, and
cerebrovasospasm.
Conclusions: Copeptin level is a useful, complementary tool to predict functional outcome and mortality after
aneurysmal subarachnoid hemorrhage.
Introduction
Copeptin, the C-terminal part of the arginine vasopres-
sin precursor peptide, is associated with the severity and
outcome of critical illness, and therefore, has been pro-
posed as a prognostic marker in acute illness [1-11].
Recently, it has been reported that plasma copeptin
levels were also elevated in the patients with traumatic
brain injury [11,12] and intracerebral hemorrhage
[10,13] and ischemic stroke [8,9]; in these groups of
patients, high copeptin levels were highly predictive for
poor outcome. However, No published information
exists to date about the association of copeptin with dis-
ease outcome and cerebrovasospasm after aneurysmal
subarachnoid hemorrhage (SAH). The present study
aimed to investigate the ability of copeptin to predict
the disease outcome and cerebrovasospasm in the
patients with aneurysmal SAH.
Materials and methods
Study population
Between July 2008 and March 2010, all patients with
aneurysmal SAH confirmed by computerized tomogra-
phy (CT) angiography with or without digital subtrac-
tion angiography who were admitted to Department of
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Medicine, Zhejiang University were evaluated in the
study. Inclusion criteria were clinical history of SAH
within the last 24 hrs before admission and the treat-
ment by surgery or coiling within the 48 hrs after
admission. Exclusion criteria were less than 18 years of
age, existing previous head trauma, neurological diseases
including ischemic or hemorrhagic stroke, use of anti-
platelet or anticoagulant medication, and presence of
other prior systemic diseases including uremia, liver cir-
rhosis, malignancy, chronic heart or lung disease, dia-
betes mellitus and hypertension.
A control group consisted of 150 healthy sex and age-
matched subjects with normal results on brain magnetic
resonance imaging and without vascular risk factors.
Written informed consent to participate in the study
was obtained from the subjects or their relatives. This
protocol was approved by the Ethics Committee of The
Second Affiliated Hospital, School of Medicine, Zhejiang
University before implementation.
Clinical and radiological assessment
On arrival to the emergency department, a detailed his-
tory of vascular risk factors, concomitant medication,
Glasgow Coma Scale (GCS) score, body temperature,
heart rate, respiratory rate and blood pressure were
taken. At admission, clinical severity was assessed using
the World Federation of Neurological Surgeons (WFNS)
score [14]. The initial CT was classified according to the
modified Fisher score [15]. All CT scans were performed
according to the neuroradiology department protocol.
Investigators who read them were blinded to clinical
information.
Patient management
The type of treatment (surgery or coiling) was decided
according to both location and size of the aneurysm by
the neurosurgeon and the neuroradiologist. All patients
received intravenous Nimodipine at a dose of 2 mg/h
from admission until at least day 14, except during peri-
ods of uncontrolled increased intracranial pressure dur-
ing which intravenous Nimodipine was discontinued.
Seizures were systematically prevented by Sodium
Valproate (200 mg × 3, per os). After surgery or coiling,
those patients who had delayed ischemic neurological
deficit or cerebrovasospasm were managed with ‘triple
H’ therapy (hypertension with a mean arterial pressure
goal greater than 100 mm Hg, hypervolemia and hemo-
dilution with a goal hematocrit of 30) through 12 days
after hemorrhage. An external ventricular drain was
inserted in case of hydrocephalus on CT and in patients
with a high WFNS grade (WFNS score of 3-5).
Increased intracranial pressure was treated by cere-
brospinal fluid drainage, mechanical ventilation,
reinforcement of sedation, and, rarely, moderate
hypothermia. CT was performed whenever clinical dete-
rioration occurred to search for secondary complications
such as hydrocephalus or ischemia.
Clinical onset of cerebral vasospasm was defined as
the acute onset of a focal neurologic deficit or a change
in the GCS score of 2 or more points. All suspected
cases of cerebral vasospasms were confirmed by CT
angiography and were then taken to the interventional
radiology suite for cerebral angiography. Each vasospasm
episode was treated with intra-arterial administration of
Nimodipine as recently described. This therapy was
repeated if necessary. Balloon Angioplasty was used as a
second-line therapy when Nimodipine was judged insuf-
ficient. Computed tomography ischemia was referred to
as delayed ischemia attributed to vasospasm.
Determination of copeptin in plasma
The informed consents were obtained from study popu-
lation or family members in all cases before the blood
were collected. In the control group, venous blood was
drawn at study entry. In the SAH patients, venous blood
was drawn on admission. The blood samples were
immediately placed into sterile EDTA test tubes and
centrifuged at 1500 g for 20 minutes at 4°C to collect
plasma. Plasma was stored at -70°C until assayed. The
concentration of copeptin in plasma was analyzed by
enzyme-linked immunosorbent assay (ELISA) using
commercial kits (Cusabio biotech co. ltd, Wuhan, Hubei
Province, China) in accordance with the manufactures’
instructions. Intra-assay and inter-assay coefficients of
variation were 4.2% and 6.8%. The blood samples were
run in duplicate. Researchers running ELISAs were
blinded to all patient details.
End point
Participants were followed up until death or completion
of one year after SAH. Their primary outcome was
death (at 1 year or in-hospital) and their secondary out-
comes were vasospasm and functional outcome at 1
year. The functional outcome was defined by Glasgow
outcome scale (GOS) score. GOS was defined as follows:
1 = death; 2 = persistent vegetative state; 3 = severe dis-
ability; 4 = moderate disability; and 5 = good recovery
[16]. GOS Scores were dichotomized in good and poor
functional outcomes (GOS of 4-5 vs. GOS of 1-3). For
follow-up, we used structure telephone interviews per-
formed by 1 doctor, blinded to clinical information and
copeptin levels.
Statistical analysis
Statistical analysis was performed with SPSS 10.0 (SPSS
Inc., Chicago, IL, USA) and MedCalc 9.6.4.0. (MedCalc
Software, Mariakerke, Belgium). The normality of data
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test or Shapiro-Wilk test. All values are expressed as
mean ± standard deviation or counts (percentage) unless
otherwise specified. Comparisons were made by using
(1) chi-square test or Fisher exact test for categorical
data, (2) unpaired Student t test for continuous normally
distributed variables, and (3) the Mann-Whitney U-test
for continuous non-normally distributed variables. The
relations of copeptin to the poor functional outcome
(GOS 1-3), death and cerebrovasospasm were assessed
in a binary logistic-regression model. For multivariate
analysis, we included the significantly different outcome
predictors as assessed in univariate analysis. A receiver
operating characteristic curve was configured to estab-
lish the cutoff point of plasma copeptin with the optimal
sensitivity and specificity forp r e d i c t i n gt h ep o o rf u n c -
tional outcome (GOS 1-3), death and cerebrovasospasm.
In a combined logistic-regression model, we estimated
the additive benefit of copeptin to other predictors
(WFNS grade and Fisher grade). A P value of less than
0.05 was considered statistically significant.
Results
Study population characteristics
During the recruitment period, 347 patients were
admitted with an initial diagnosis of aneurysmal SAH,
312 (89.9%) patients fulfilled the inclusion criteria, and
adequate data on admission and follow-up were avail-
able for 303 individuals (87.3%) who were finally
included in the analysis (Figure 1). Table 1 summarized
the demographic, clinical, laboratory and radiological
data of the patients.
The change in plasma copeptin level on admission in
patients with SAH
After SAH, plasma copeptin level on admission in
patients was statistically significantly higher than that in
healthy controls (21.2 ± 9.0 pmol/L vs. 6.4 ± 1.8 pmol/
L; P < 0.001)(Figure 2).
One-year mortality prediction
Forty-two patients (13.9%) died from SAH in one year.
Higher plasma copeptin level was associated with one-
year mortality, as well as other variables shown in the
Table 2. When the above variables found to be signifi-
cant in the univariate analysis were introduced into the
logistic model, A multivariate analysis selected WFNS
score, modified Fisher score and plasma copeptin level
as the independent predictors for one-year mortality of
patients (Table 3).
A receiver operating characteristic curve showed that
plasma copeptin level on admission predicted one-year
mortality of patients statistically significantly (Figure
3A). The predictive value of the copeptin concentration
was similar to those of WFNS score and modified Fisher
score (Table 4). In a combined logistic-regression model,
copeptin did not statistically significantly improved the
area under curve of WFNS score (P = 0.125) and modi-
fied Fisher score (P = 0.164).
In-hospital mortality prediction
Thirty-two patients (10.6%) died from SAH in the hospi-
tal. Higher plasma copeptin level was associated with in-
hospital mortality, as well as other variables shown in
t h eT a b l e5 .W h e nt h ea b o v ev a r i a b l e sf o u n dt ob es i g -
nificant in the univariate analysis were introduced into
the logistic model, a multivariate analysis selected
WFNS score, modified Fisher score and plasma copeptin
level as the independent predictors for in-hospital mor-
tality of patients (Table 6).
A receiver operating characteristic curve showed that
plasma copeptin level on admission predicted in-hospital
mortality of patients statistically significantly (Figure 3B).
The predictive value of the copeptin concentration was
similar to those of WFNS score and modified Fisher
score (Table 7). In a combined logistic-regression
model, copeptin did not statistically significantly
improved the area under curve of WFNS score (P =
0.148) and modified Fisher score (P = 0.135).
Cerebrovasospasm prediction
One hundred and thirty-one (43.2%) suffered from cere-
brovasospasm in the hospital. Higher plasma copeptin
level was associated with cerebrovasospasm, as well as
other variables shown in the Table 8. When the above
variables found to be significant in the univariate analy-
sis were introduced into the logistic model, a multivari-
ate analysis selected WFNS score, modified Fisher score
and plasma copeptin level as the independent predictors
for cerebrovasospasm of patients (Table 9).
A receiver operating characteristic curve showed that
plasma copeptin level on admission predicted cerebrova-
sospasm of patients statistically significantly (Figure 3C).
The predictive value of the copeptin concentration was
lower than those of WFNS score and modified Fisher
score (Table 10). In a combined logistic-regression
model, copeptin did not statistically significantly
improved the area under curve of WFNS score (P =
0.206) and modified Fisher score (P = 0.288).
Poor neurologic function prediction
Ninety patients (29.7%) suffered from poor neurologic
outcome (GOS 1-3) in one year. Higher plasma copeptin
level was associated with one-year poor neurologic out-
come, as well as other variables shown in the Table 11.
When the above variables found to be significant in the
univariate analysis were introduced into the logistic
model, a multivariate analysis selected WFNS score,
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independent predictors for one-year poor neurologic
outcome of patients (Table 12).
A receiver operating characteristic curve showed that
plasma copeptin level on admission predicted one-year
poor neurologic outcome of patients statistically signifi-
cantly (Figure 3D). The predictive value of the copeptin
concentration was similar to those of WFNS score and
modified Fisher score (Table 13). In a combined logis-
tic-regression model, copeptin statistically significantly
improved the area under curve of WFNS score (P =
0.018) and modified Fisher score (P = 0.029).
Discussion
In this retrospective study, we aimed to investigate the
plasma copeptin levels in the SAH patients, and there-
fore, presence of other prior systemic diseases including
uremia, liver cirrhosis, malignancy, chronic heart or
lung disease, diabetes mellitus and hypertension, that
may be associated with plasma copeptin levels [1-7,17],
may become the confounding variables, and finally, were
excluded. Furthermore, we demonstrated that plasma
copeptin levels on admission in the patients were signifi-
cantly higher than those in healthy controls; and in
patients who had poor functional outcome or died in a
year or die in hospital, the copeptin levels on admission
were significantly higher compared with levels in survi-
vors or patients with good functional outcome. In multi-
variate logistic regression models of predictors of death
and poor functional outcomet h a ti n c l u d e do t h e rc o n -
founding variables previously reported [18-20], the
copeptin levels on admission were an independent pre-
dictor. Need to mention, of two patients with basilar tip
aneurysms in this study, one refused to treat and the
other had missing of follow up. And therefore, they
could be included in this study. In addition, in this
study, plasma copeptin level for these patients (turning
point: 23.8 pmol/L) was similar to that of intracerebral
hemorrhage (turning point: 18 pmol/L) [9] or ischemic
stroke (turning point: 16.3 pmol/L) [10] in previous
reports. Grade III is typically associated with worse
poorer outcome. This result was verified by receiver
Figure 1 Graph documenting patients’ entry into the study from screening.
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under curve. Recently, various risk factors for poor out-
come after SAH have been identified, and include age,
WFNS grade, aneurysmal size, vasospasm, clot thickness
and so on [17]. In this study, aneurysmal size, vasos-
pasm, computed tomography ischemia and so on were
highly associated with poor outcome in univariate analy-
sis, but they were not in multivariate analysis. However,
WFNS grade, modified Fisher grade and plasma copep-
tin level were identified as independent predictors for
poor outcome. Generally, in few reports, biochemical
markers were assessed. In this study, some biochemical
markers were included. However, if larger sample size
are obtained, these factors such as vasospasm and com-
puted tomography ischemia, which are probably equally
important, will be included multivariate model. And
therefore, it is possible that different variables included
in these studies and study designs led to these
differences. In addition, in previous exploratory analysis,
aneurysm coiling was associated with less angiographic
vasospasm and delayed ischemic neurological deficit
than surgical clipping; furthermore, Dumont et al. still
suggested whether this is attributable to differences in
baseline risk factors between clipped and coiled patients
o rat r u ed i f f e r e n c er e m a i n e dt ob ep r o v e n[ 2 1 ] .H o w -
ever, our study did not show better outcomes and less
angiographic vasospasm for coiled patients. Thus, final
conclusion remains to be verified.
Copeptin is co-synthesized with arginine vasopressin in
the hypothalamus and is released into the portal circula-
tion of the neurohypophysis. Arginine vasopressin contri-
butes to the regulation of osmotic and cardiovascular
homeostasis [22,23]. In addition, arginine vasopressin acti-
vates the hypothalamo - pituitary - adrenal axis through
potentiation of corticotrophin - releasing - hormone -
induced adrenocorticotropic hormone secretion and thus
reflects the individual stress response at a hypothalamic
level [24,25]. Copeptin concentrations mirror that of argi-
nine vasopressin [26]. Copeptin is known to have prognos-
tic value in a variety of diseases, as it reflects disease
severity and thus the chance of recovery. For example,
copeptin levels have prognostic implications in patients
with hemorrhagic and septic shock, lower respiratory tract
infection and acute heart failure [1-11]. Therefore, it has
been hypothesized that the close and reproducible relation
of copeptin levels to the degree of activation of the stress
axis is the basis of its unique usefulness as a prognostic
biomarker [8]. In addition, data from experimental studies
imply that vasopressin plays a role in brain edema forma-
tion as blocking of vasopressin receptors attenuates brain
edema in ischemic and traumatic mice models [27-29].
The relationship between vasopressin levels and brain
edema development has also been demonstrated in a clini-
cal study of head injured patients [30]. Hence, the implica-
tion of copeptin and brain edema formation in SAH
remains hypothetical at the moment.
Copeptin comes from the same precursor as mature
arginine vasopressin, which is already well associated
with hemodynamic changes and patient outcome. The
measurement of mature arginine vasopressin, however, is
subject to considerable challenges, and has therefore not
reached clinical routine in the context of rapid measure-
ments in the critically ill patients. Here, the stability and
longer ex vivo half-life of copeptin is a practical advan-
tage, which makes it easier to determine in the clinical
laboratory. In this study, a receiver operating characteris-
tic curve showed that plasma copeptin level on admission
predicted poor functional outcome and mortality after 1
year, and in-hospital mortality of patients obviously. The
area under curve of the copeptin concentration was simi-
lar to those of WFNS score and modified Fisher score for
the prediction of these poor outcomes. In a combined
Table 1 The characteristics for 303 patients
Characteristics
Sex (male/female) 131/172
Age (y) 43.9 ±
12.4
World Federation of Neurological Surgeons score on
admission
2.3 ± 1.2
Modified Fisher score on admission 2.7 ± 1.0
Aneurysmal location
Posterior communication artery 83 (27.4%)
Internal carotid artery 43 (14.2%)
Anterior communication artery 66 (21.8%)
Middle cerebral artery 45(14.9%)
Anterior cerebral artery 35 (11.6%)
Posterior cerebral artery 23 (7.6%)
Vertebral artery 8 (2.6%)
Surgery 186
(61.4%)
Aneurysmal size (mm) 7.2 ± 4.9
Rebleeding 16 (5.3%)
Acute hydrocephalus 90 (29.7%)
Intracerebral hemorrhage 39 (12.9%)
Intraventricular hemorrhage 72 (23.8%)
External ventricular drain 109
(36.0%)
Angiographic vasospasm 131
(43.2%)
Computed tomography ischemia 50 (16.5%)
Admission time (hr) 4.7 ± 3.6
Plasma-sampling time (hr) 6.7 ± 4.4
Seizure 44 (14.5%)
Plasma C-reactive protein level (mg/L) 7.1 ± 2.7
plasma D-dimer level (mg/L) 2.1 ± 0.9
Plasma copeptin level (pmol/L) 21.2 ± 9.0
Numerical variables were presented as mean ± standard deviation. Categorical
variables were expressed as counts (percentage).
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Page 5 of 13Figure 2 Graph showing the change of plasma copeptin concentration in the patients with aneurysmal subarachnoid hemorrhage.
Data are expressed as mean ± standard deviation.
Table 2 The factors associated with one-year mortality
Non-survivals
(n = 42)
Survival
(n = 261)
P value
Sex (male/female) 18/24 113/148 0.958
Age (y) 45.4 ± 13.4 43.6 ± 12.2 0.389
WFNS score on admission 4.0 ± 0.7 2.1 ± 1.0 <0.001
Modified Fisher score on admission 4.2 ± 0.6 2.5 ± 0.8 <0.001
Aneurysmal location 0.614
Posterior communication artery 8 (19.0%) 75 (28.7%)
Internal carotid artery 6 (14.3%) 37(14.2%)
Anterior communication artery 9 (21.4%) 57 (21.8%)
Middle cerebral artery 7 (16.7%) 38 (14.6%)
Anterior cerebral artery 6 (14.3%) 29 (11.1%)
Posterior cerebral artery 4 (9.5%) 19 (7.3%)
Vertebral artery 2 (4.8%) 6 (2.3%)
Surgery 21 (50.0%) 165 (63.2%) 0.102
Aneurysmal size (mm) 11.1 ± 5.3 6.6 ± 4.5 <0.001
Rebleeding 10 (23.8%) 6 (2.3%) <0.001
Acute hydrocephalus 25 (59.5%) 65 (24.9%) 0.001
Intracerebral hemorrhage 19 (45.2%) 20 (7.7%) <0.001
Intraventricular hemorrhage 37 (88.1%) 35 (13.4%) <0.001
External ventricular drain 38 (90.5%) 71 (27.2%) <0.001
Angiographic vasospasm 38 (90.5%) 93 (35.6%) <0.001
Computed tomography ischemia 18 (42.9%) 32 (12.3%) <0.001
Admission time (hr) 5.5 ± 4.4 4.6 ± 3.5 0.128
Seizure 9 (21.4%) 35 (13.4%) 0.171
Plasma C-reactive protein level (mg/L) 8.7 ± 3.3 6.9 ± 2.6 <0.001
plasma D-dimer level (mg/L) 2.4 ± 1.0 2.0 ± 1.0 0.015
Plasma copeptin level (pmol/L) 31.4 ± 8.3 19.5 ± 8.0 <0.001
Numerical variables were presented as mean ± standard deviation. Categorical variables were expressed as counts (percentage). Numerical variables were
analyzed by Mann-Whitney U-test or unpaired Student t test. Categorical variables were analyzed by chi-square test or Fisher exact test. n indicates number of
patients; WFNS, World Federation of Neurological Surgeons.
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under curve of WFNS score and modified Fisher score
for the prediction of poor functional outcome after 1
year, but not for the prediction of mortality after 1 year
or in-hospital mortality. Therefore, the determination of
copeptin in the plasma of patients on admission provides
the ability to distinguish between patients with good and
bad outcome.
Table 3 Multivariate analysis of factors predicting the one-year mortality among 303 patients
Odds ratio 95% confidence interval P value
WFNS score on admission 7.530 1.351~20.642 0.002
Modified Fisher score on admission 9.181 2.236~22.297 0.006
Aneurysmal size (mm) 1.182 0.914~1.324 0.361
Rebleeding 4.243 0.624~26.748 0.311
Acute hydrocephalus 1.249 0.230~25.387 0.401
Intracerebral hemorrhage 1.235 0.642~6.891 0.183
Intraventricular hemorrhage 3.822 0.893~11.402 0.064
External ventricular drain 1.105 0.611~4.008 0.397
Angiographic vasospasm 2.164 0.912~6.217 0.132
Computed tomography ischemia 1.472 0.881~5.438 0.271
Plasma C-reactive protein level (mg/L) 1.104 0.861~1.945 0.401
plasma D-dimer level (mg/L) 0.941 0.573~1.908 0.781
Plasma copeptin level (pmol/L) 2.307 1.324~6.974 0.004
The relation of copeptin to the mortality was assessed in a logistic-regression model. WFNS indicates World Federation of Neurological Surgeons.
Figure 3 Graph showing receiver operating characteristic curve analysis of plasma copeptin level for one-year mortality (3A), in-
hospital mortality (3B), cerebrovasospasm (3C) and one-year poor functional outcome (3D).
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patients
Copeptin WFNS score Modified Fisher score
Criterion >20.5 pmol/L >3 >3
Area under curve 0.868 0.920 0.927
95% confidence interval 0.824 ~ 0.904 0.884 ~ 0.948 0.892~0.954
Sensitivity 92.9 78.6 88.1
95% confidence interval 80.5 ~98.4 63.2 ~89.7 74.4 ~96.0
Specificity 70.1 90.4 86.6
95% confidence interval 64.2 ~ 75.6 86.2~93.7 81.8~90.5
Odds ratio 29.949 34.613 47.743
95% confidence interval 8.998~99.796 14.876~80.563 17.579~129.667
+ likelihood ratio 3.11 8.20 6.57
95% confidence interval 2.8 ~3.5 7.0~ 9.7 5.8 ~7.4
- likelihood ratio 0.10 0.24 0.14
95% confidence interval 0.03~ 0.3 0.1 ~0.5 0.06 ~0.3
P value Reference 0.197 0.155
WFNS indicates World Federation of Neurological Surgeons.
Table 5 The factors associated with in-hospital mortality
Non-survivals
(n = 32)
Survival
(n = 271)
P value
Sex (male/female) 12/20 119/152 0.489
Age (y) 45.4 ± 12.9 43.7 ± 12.3 0.469
WFNS score on admission 3.9 ± 0.7 2.2 ± 1.1 <0.001
Modified Fisher score on admission 4.3 ± 0.6 2.6 ± 0.8 <0.001
Aneurysmal location 0.599
Posterior communication artery 5 (15.6%) 78 (28.8%)
Internal carotid artery 6 (18.8%) 37(13.7%)
Anterior communication artery 8 (25.0%) 58 (21.4%)
Middle cerebral artery 4 (12.5%) 41 (15.1%)
Anterior cerebral artery 4 (12.5%) 31 (11.4%)
Posterior cerebral artery 3 (9.4%) 20 (7.4%)
Vertebral artery 2 (6.3%) 6 (2.2%)
Surgery 17 (53.1%) 169 (62.4%) 0.310
Aneurysmal size (mm) 11.9 ± 5.1 6.7 ± 4.5 <0.001
Rebleeding 6 (18.8%) 10 (3.7%) <0.001
Acute hydrocephalus 19 (59.4%) 71 (26.2%) <0.001
Intracerebral hemorrhage 15 (46.9%) 24 (8.9%) <0.001
Intraventricular hemorrhage 31 (96.9%) 41 (15.1%) <0.001
External ventricular drain 30 (93.8%) 79 (29.2%) <0.001
Angiographic vasospasm 30 (93.8%) 101 (37.3%) <0.001
Computed tomography ischemia 16 (50.0%) 34 (12.6%) <0.001
Admission time (hr) 5.4 ± 4.2 4.6 ± 3.6 0.276
Seizure 7 (21.9%) 37 (13.7%) 0.212
Plasma C-reactive protein level (mg/L) 9.0 ± 3.2 6.9 ± 2.6 <0.001
plasma D-dimer level (mg/L) 2.4 ± 1.1 2.0 ± 1.0 0.045
Plasma copeptin level (pmol/L) 31.8 ± 8.5 19.9 ± 8.2 <0.001
Numerical variables were presented as mean ± standard deviation. Categorical variables were expressed as counts (percentage). Numerical variables were
analyzed by Mann-Whitney U-test or unpaired Student t test. Categorical variables were analyzed by chi-square test or Fisher exact test. n indicates number of
patients; WFNS, World Federation of Neurological Surgeons.
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longed smooth muscle contraction of cerebral arteries;
many substances have been involved in the develop-
ment of cerebral vasospasm following SAH, but the
complex mechanism of this arterial narrowing is not
yet fully understood [31,32]. Some authors have
reported that arginine vasopressin may play a role in
the development of cerebral vasospasm [33,34] and
ischemic brain edema [35,36]. Arginine vasopressin
causes vasoconstriction in rabbit, feline, goat, rat and
human [37-41]. In a model of SAH in rats, Delgado et
al. demonstrated a biphasic, angiographically visible
vasospasm with maximum acute vasospasm at 10 min
after SAH and maximum late vasospasm 2 days later
[42]. It was also shown that intracisternal injection of
AVP determined acute vasospasm with a time-course
similar to that seen in normal rats after SAH [34].
These studies sustain a better understanding of the
role of arginine vasopressin in the cerebrovasospasm
following SAH. Copeptin concentrations mirror that of
arginine vasopressin [26]. Coupled with our observa-
tion that plasma copeptin level was an independent
predictor for cerebrovasospasm of patients, the impli-
cation of copeptin and cerebrovasospasm formation in
SAH remains hypothetical at the moment. Grade III is
typically associated with the formation of vasospasm.
This result was verified by receiver operating charac-
teristic curve analysis with high area under curve.
However, significantly lower accuracy for the predic-
tion of cerebrovasospasm was found for plasma copep-
tin level compared with other clinical grade such as
WFNS and modified Fisher grade. Hence, plasma levels
of copeptin on admission are not recommended for
the prediction of cerebrovasospasm after SAH.
Table 6 Multivariate analysis of factors predicting the in-hospital mortality among 303 patients
Odds ratio 95% confidence interval P value
WFNS score on admission 4.973 1.497~13.137 0.003
Modified Fisher score on admission 5.982 2.469~17.149 0.001
Aneurysmal size (mm) 1.218 0.909~1.423 0.103
Rebleeding 1.483 0.882~5.492 0.163
Acute hydrocephalus 1.097 0.711~4.483 0.242
Intracerebral hemorrhage 1.479 0.703~5.176 0.207
Intraventricular hemorrhage 3.94 0.816~9.407 0.096
External ventricular drain 2.009 0.518~5.36 0.148
Angiographic vasospasm 2.930 0.918~7.998 0.091
Computed tomography ischemia 1.482 0.683~5.004 0.315
Plasma C-reactive protein level (mg/L) 1.455 0.673~2.947 0.482
plasma D-dimer level (mg/L) 0.915 0.587~2.936 0.367
Plasma copeptin level (pmol/L) 2.515 1.399~8.229 0.002
The relation of copeptin to the mortality was assessed in a logistic-regression model. WFNS indicates World Federation of Neurological Surgeons.
Table 7 Receiver operating characteristic curve analysis of factors predicting the in-hospital mortality among 303
patients
Copeptin WFNS score Modified Fisher score
Criterion >28.7 pmol/L >3 >3
Area under curve 0.868 0.893 0.922
95% confidence interval 0.825 ~0.904 0.853 ~ 0.926 0.886~0.950
Sensitivity 78.1 75.0 90.6
95% confidence interval 60.0 ~90.7 56.6 ~88.5 75.0 ~97.9
Specificity 89.7 87.5 84.1
95% confidence interval 85.4 ~ 93.0 82.9~91.2 79.2~88.3
Odds ratio 29.798 20.911 51.254
95% confidence interval 11.847~74.946 8.698~50.270 14.944~105.792
+ likelihood ratio 7.56 5.98 5.71
95% confidence interval 6.3 ~9.1 4.9~ 7.3 5.1 ~6.5
- likelihood ratio 0.24 0.29 0.11
95% confidence interval 0.1~ 0.5 0.1 ~0.6 0.04 ~0.3
P value Reference 0.613 0.246
WFNS indicates World Federation of Neurological Surgeons.
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Page 9 of 13Table 8 The factors associated with cerebrovasospasm
Vasospasm
(n = 131)
Non-vasospasm
(n = 172)
P value
Sex (male/female) 61/70 70/102 0.307
Age (y) 43.8 ± 12.2 43.9 ± 12.5 0.973
WFNS score on admission 3.2 ± 1.1 1.7 ± 0.9 <0.001
Modified Fisher score on admission 3.5 ± 1.0 2.2 ± 0.6 <0.001
Aneurysmal location 0.813
Posterior communication artery 33 (25.2%) 50 (29.1%)
Internal carotid artery 20 (15.3%) 23(13.4%)
Anterior communication artery 29 (22.1%) 37 (21.5%)
Middle cerebral artery 22 (16.8%) 23 (13.4%)
Anterior cerebral artery 16 (12.2%) 19 (11.0%)
Posterior cerebral artery 7 (5.3%) 16 (9.3%)
Vertebral artery 4 (3.1%) 4 (2.3%)
Surgery 86 (65.5%) 100 (58.1%) 0.183
Aneurysmal size (mm) 9.1 ± 5.7 5.8 ± 3.5 <0.001
Rebleeding 10 (7.6%) 6 (3.5%) 0.110
Acute hydrocephalus 71 (54.2%) 19 (11.0%) <0.001
Intracerebral hemorrhage 26 (19.9%) 13(7.6%) 0.002
Intraventricular hemorrhage 52 (39.7%) 20 (11.6%) <0.001
External ventricular drain 90 (68.7%) 19 (11.0%) <0.001
Admission time (hr) 4.5 ± 3.4 4.9 ± 3.8 0.342
Seizure 17 (13.0%) 27 (15.7%) 0.505
Systolic arterial pressure (mmHg) 134.2 ± 23.6 128.7 ± 21.2 0.033
Diastolic arterial pressure (mmHg) 81.1 ± 15.1 77.5 ± 13.8 0.031
Mean arterial pressure (mmHg) 98.8 ± 16.1 94.6 ± 15.3 0.020
Plasma C-reactive protein level (mg/L) 7.9 ± 3.0 6.6 ± 2.4 <0.001
plasma D-dimer level (mg/L) 2.2 ± 1.1 1.9 ± 0.9 0.011
Plasma copeptin level (pmol/L) 25.0 ± 8.4 18.3 ± 8.3 <0.001
Numerical variables were presented as mean ± standard deviation. Categorical variables were expressed as counts (percentage). Numerical variables were
analyzed by Mann-Whitney U-test or unpaired Student t test. Categorical variables were analyzed by chi-square test or Fisher exact test. n indicates number of
patients; WFNS, World Federation of Neurological Surgeons.
Table 9 Multivariate analysis of factors predicting the cerebrovasospasm among 303 patients
Odds ratio 95% confidence interval P value
WFNS score on admission 3.988 1.248~8.909 0.005
Modified Fisher score on admission 4.692 1.627~15.726 0.001
Aneurysmal size (mm) 1.104 0.998~1.247 0.061
Acute hydrocephalus 1.548 0.932~4.877 0.078
Intracerebral hemorrhage 1.709 0.437~5.174 0.514
Intraventricular hemorrhage 2.472 0.911~6.972 0.060
External ventricular drain 1.615 0.604~6.183 0.176
Systolic arterial pressure (mmHg) 1.012 0.989~1.214 0.612
Diastolic arterial pressure (mmHg) 1.003 0.972~1.044 0.622
Mean arterial pressure (mmHg) 1.005 0.901~1.103 0.583
Plasma C-reactive protein level (mg/L) 0.893 0.713~1.082 0.204
plasma D-dimer level (mg/L) 0.829 0.519~1.327 0.595
Plasma copeptin level (pmol/L) 1.292 1.149~1.605 0.025
The relation of copeptin to the mortality was assessed in a logistic-regression model. WFNS indicates World Federation of Neurological Surgeons.
Zhu et al. Critical Care 2011, 15:R288
http://ccforum.com/content/15/6/R288
Page 10 of 13Table 10 Receiver operating characteristic curve analysis of factors predicting the cerebrovasospasm among 303
patients
Copeptin WFNS score Modified Fisher score
Criterion >23.4 pmol/L >2 >2
Area under curve 0.792 0.879 0.874
95% confidence interval 0.742 ~0.836 0.837 ~ 0.913 0.831~0.909
Sensitivity 69.2 80.9 84.7
95% confidence interval 60.8 ~77.4 73.1 ~87.3 77.4 ~90.4
Specificity 84.9 79.7 76.7
95% confidence interval 78.6 ~ 89.9 72.9~85.4 69.4~82.2
Odds ratio 7.783 9.488 7.814
95% confidence interval 4.617~13.121 5.597~16.085 4.663~13.096
+ likelihood ratio 4.60 3.98 3.64
95% confidence interval 4.0 ~5.2 3.6~ 4.4 3.3 ~4.1
- likelihood ratio 0.36 0.24 0.20
95% confidence interval 0.2~ 0.6 0.2 ~0.4 0.1 ~0.3
P value Reference 0.002 0.006
WFNS indicates World Federation of Neurological Surgeons.
Table 11 The factors associated with one-year function outcome
GOS 1-3
(n = 90)
GOS 4-5
(n = 213)
P value
Sex (male/female) 42/48 89/124 0.433
Age (y) 44.7 ± 11.3 43.5 ± 12.8 0.422
WFNS score on admission 3.6 ± 0.7 1.8 ± 0.9 <0.001
Modified Fisher score on admission 3.8 ± 0.8 2.3 ± 0.7 <0.001
Aneurysmal location 0.291
Posterior communication artery 24 (26.7%) 59 (27.7%)
Internal carotid artery 13 (14.4%) 30(14.1%)
Anterior communication artery 17 (18.9%) 49 (23.0%)
Middle cerebral artery 14 (15.6%) 31 (14.6%)
Anterior cerebral artery 7 (7.8%) 28 (13.1%)
Posterior cerebral artery 11 (12.2%) 12 (5.6%)
Vertebral artery 4 (4.4%) 4 (1.9%)
Surgery 54 (60.0%) 132 (62.0%) 0.747
Aneurysmal size (mm) 10.4 ± 5.8 5.9 ± 3.7 <0.001
Rebleeding 10 (11.1%) 6 (2.8%) 0.003
Acute hydrocephalus 47 (52.2%) 43 (20.2%) <0.001
Intracerebral hemorrhage 20 (22.2%) 19 (8.9%) 0.002
Intraventricular hemorrhage 59(65.6%) 12 (5.6%) <0.001
External ventricular drain 66 (73.3%) 43 (20.2%) <0.001
Angiographic vasospasm 71 (78.9%) 60 (28.2%) <0.001
Computed tomography ischemia 28 (31.1%) 22 (10.3%) <0.001
Admission time (hr) 4.5 ± 3.5 4.8 ± 3.7 0.577
Seizure 19 (21.1%) 25 (11.7%) 0.085
Plasma C-reactive protein level (mg/L) 8.2 ± 3.2 6.7 ± 2.4 <0.001
plasma D-dimer level (mg/L) 2.4 ± 1.2 1.9 ± 0.9 <0.001
Plasma copeptin level (pmol/L) 29.3 ± 9.0 17.8 ± 6.4 <0.001
Numerical variables were presented as mean ± standard deviation. Categorical variables were expressed as counts (percentage). Numerical variables were
analyzed by Mann-Whitney U-test or unpaired Student t test. Categorical variables were analyzed by chi-square test or Fisher exact test. n indicates number of
patients; WFNS, World Federation of Neurological Surgeons; GOS, Glasgow Outcome Scale.
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In this study, plasma copeptin level is a useful, comple-
mentary tool to predict functional outcome and mortal-
ity after aneurysmal subarachnoid hemorrhage.
Key messages
￿ In the patients with aneurysmal subarachnoid
hemorrhage, plasma copeptin level was substantially
higher than that in healthy controls.
￿ Plasma copeptin level was an independent predic-
tor of functional outcome and death after aneurys-
mal subarachnoid hemorrhage
￿ Copeptin level was a useful, complementary tool to
predict functional outcome and mortality after
aneurysmal subarachnoid hemorrhage.
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Table 12 Multivariate analysis of factors predicting one-year poor functional outcome among 303 patients
Odds ratio 95% confidence interval P value
WFNS score on admission 4.930 1.997~13.438 0.005
Modified Fisher score on admission 5.743 2.502~16.307 0.001
Aneurysmal size (mm) 1.129 0.782~1.337 0.137
Rebleeding 1.219 0.841~9.090 0.103
Acute hydrocephalus 1.132 0.730~8.004 0.218
Intracerebral hemorrhage 2.670 0.470~14.003 0.314
Intraventricular hemorrhage 2.404 0.817~12.337 0.087
External ventricular drain 1.316 0.718~4.796 0.316
Angiographic vasospasm 1.174 0.790~3.931 0.113
Computed tomography ischemia 1.422 0.849~3.640 0.139
Plasma C-reactive protein level (mg/L) 1.019 0.827~1.213 0.709
plasma D-dimer level (mg/L) 1.182 0.762~1.899 0.418
Plasma copeptin level (pmol/L) 1.253 1.109~1.504 0.001
The relation of copeptin to the poor functional outcome was assessed in a logistic-regression model. WFNS indicates World Federation of Neurological Surgeons.
Table 13 Receiver operating characteristic curve analysis of factors predicting one-year poor functional outcome
among 303 patients
Copeptin WFNS score Modified Fisher score
Criterion >23.8 pmol/L >2 >2
Area under curve 0.860 0.909 0.902
95% confidence interval 0.815~0.897 0.871~0.939 0.863~0.933
Sensitivity 82.2 96.7 95.6
95% confidence interval 72.7~89.5 90.6~99.3 89.0 ~98.7
Specificity 79.8 74.7 69.5
95% confidence interval 73.8~85.0 68.3 ~80.3 62.8~75.6
Odds ratio 18.284 85.228 48.941
95% confidence interval 9.684~34.522 25.912~280.325 17.237~139.015
+ likelihood ratio 4.07 3.81 3.13
95% confidence interval 3.6~4.6 3.5~4.2 2.8 ~3.5
- likelihood ratio 0.22 0.045 0.064
95% confidence interval 0.1~0.4 0.01 ~0.1 0.02 ~0.2
P value Reference 0.109 0.178
WFNS indicates World Federation of Neurological Surgeons.
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